MAP9

Across TCGA pan-cancer cohorts, MAP9 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MAP9’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where MAP9 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MAP9 is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

LSCC, PDAC, and CCRCC are the cancer types where MAP9 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP9 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	−0.259	<.001	4	view →
PDAC	Male	All	−0.309	.029	1	view →
CCRCC	All	III,IV	−0.209	.030	1	view →
LUAD	All	All	−0.109	.012	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MAP9–LSCC

Open the LSCC breakdown →